BRGX.OIDBioregenx, INC
8-K: BioRegenx Completes Merger, Focuses on Growth and Product Expansion
Sentiment:
Merger Announcement
BioRegenx, Inc. has successfully completed its merger with Findit, Inc., and is now focused on expanding its product offerings and market presence.
Better than expectedThe merger completion and the launch of the updated GlycoCheck device are positive developments.The strong sales growth of Endocalyx Pro and the potential revenue from DocSun's technology are better than expected.
Summary
- BioRegenx, Inc. has completed its merger with Findit, Inc., becoming a publicly-traded entity.
- The company's name has officially changed to BioRegenx, Inc., and they are working on a new stock symbol.
- BioRegenx is aiming to uplist to the OTC QB market.
- Their subsidiary, Microvascular Health Solutions, has launched an updated GlycoCheck device with enhanced hardware and software, priced between $22,000 and $32,000, generating recurring monthly revenue.
- Favorable financing options are available for GlycoCheck customers.
- Endocalyx Pro, a dietary supplement, is experiencing strong monthly sales growth.
- BioRegenx is increasing sales and marketing efforts in 2024, expecting GlycoCheck to boost Endocalyx Pro sales.
- DocSun Biomedical Holdings, recently acquired, is set to generate revenue through a distribution agreement for its AI Engine technology, with initial revenues from SDK testing in fleet and EVs.
- DocSun will receive 40% of all revenue, including a $10 per vehicle license fee from an EV manufacturer.
- The company is enhancing DocSun's AI capabilities through hardware and software upgrades.
Sentiment
Score: 8
Explanation: The document conveys a positive outlook with the successful merger, product launches, and revenue generation potential. The company is actively pursuing growth and market expansion.
Positives
- The merger completion provides BioRegenx with new opportunities as a publicly-traded company.
- The updated GlycoCheck device is generating recurring revenue and has favorable financing options.
- Endocalyx Pro is experiencing consistent sales growth.
- The acquisition of DocSun Biomedical Holdings and its distribution agreement offer significant revenue potential.
- The company is actively working on product enhancements and market expansion.
Negatives
- The company is still working with FINRA to finalize the name and symbol change.
- The company is reliant on the success of its distribution agreement with DocSun.
- The company is reliant on the success of the GlycoCheck device and Endocalyx Pro sales.
Risks
- The company faces risks related to the timely development and delivery of products.
- There is a risk of potential customers being unable to pay for ordered products.
- The company is exposed to political and economic risks inherent in international trade.
- The company is reliant on the success of the DocSun distribution agreement.
- The company is reliant on the success of the GlycoCheck device and Endocalyx Pro sales.
Future Outlook
BioRegenx is focused on increasing sales and marketing efforts in 2024, with the integration of GlycoCheck expected to boost Endocalyx Pro sales. The company anticipates commercialization of DocSun's technology in late Q3 or early Q4.
Management Comments
- Bill Resides, CEO of BioRegenx, stated that he is extremely pleased with the milestones achieved and the growth witnessed across all four subsidiaries.
- Bill Resides also remarked that the completion of the merger marks a significant milestone, opening up new opportunities as a publicly-traded entity.
Industry Context
This announcement reflects a trend in the healthcare industry towards integrating advanced technology and data analysis for improved patient outcomes. The focus on non-invasive medical devices and wellness solutions aligns with the growing demand for preventative and personalized healthcare.
Comparison to Industry Standards
- The GlycoCheck device, with its focus on microvascular health, competes with other diagnostic tools in the market, such as those offered by companies like Vascular Solutions, Inc. and Medtronic, though these may not be directly comparable in terms of technology.
- The dietary supplement market for products like Endocalyx Pro is highly competitive, with companies like Nestle Health Science and Abbott Nutrition offering a wide range of nutritional products.
- DocSun's AI Engine technology for vital signs monitoring is similar to products offered by companies like Masimo and Philips Healthcare, but the specific application in fleet and EV vehicles is a unique market niche.
- The 40% revenue share for DocSun is a significant percentage, which is higher than some typical distribution agreements, indicating a strong potential for revenue generation.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Raymond Firth | William Resides | March 8, 2024 | Merger |
| Interim Financial Officer | Raymond Firth | William Resides | March 8, 2024 | Merger |
| Executive Vice President | Robert Doran | March 8, 2024 | Merger | |
| Chief Operating Officer | Sherri Adams | March 8, 2024 | Merger | |
| Secretary | Gary Hennerberg | March 8, 2024 | Merger | |
| Director | Raymond Firth | William Resides | March 8, 2024 | Merger |
| Director | Robert Doran | March 8, 2024 | Merger | |
| Director | Sherri Adams | March 8, 2024 | Merger | |
| Director | Gary Hennerberg | March 8, 2024 | Merger | |
| Director | Suzanne Bird | March 8, 2024 | Merger | |
| Director | Jody Walker | March 8, 2024 | Merger | |
| Director | Gary Kiss | March 8, 2024 | Merger |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorized Shares | The authorized common stock was increased to One Billion Five Hundred Thousand (1,500,000,000) common shares. | March 8, 2024 | This change provides the company with more flexibility for future capital raising and stock issuances. |
| Name Change | The name of the Registrant was changed to BioRegenx, Inc. | March 8, 2024 | This change reflects the new identity of the company after the merger. |
| Series A Preferred Shares | The company filed a Certificate of Designation and a Certificate of Correction to cure the 2013 creation of the Series A preferred shares and ratifying the issuances of 5,000,000 Series A preferred shares in 2013 which were retired pursuant to the terms of the merger. | March 14, 2024 | This action corrected a past filing error and ratified the issuance of the Series A preferred shares. |
Stakeholder Impact
- Shareholders will see a change in the company's name and stock symbol.
- Employees will be part of a newly merged entity with new leadership.
- Customers will have access to new and enhanced products.
- Suppliers will be part of a larger supply chain.
- Creditors will be dealing with a new entity.
Next Steps
- BioRegenx will continue to work with FINRA to finalize the name and symbol change.
- The company will focus on uplisting to the OTC QB market.
- BioRegenx will intensify sales and marketing efforts for GlycoCheck and Endocalyx Pro.
- The company will proceed with the commercialization of DocSun's technology in late Q3 or early Q4.
Key Dates
| Date | Description |
|---|---|
| 2013 | The company authorized the creation of 50,000,000 Series A Preferred Shares, but the Certificate of Designation was not properly filed. |
| December 29, 2022 | The definitive merger agreement between Findit, Inc. and BioRegenx, Inc. was dated. |
| January 6, 2023 | The merger agreement was disclosed in a Current Report on Form 8-K. |
| February 26, 2024 | Articles of Merger were filed with the state of Nevada. |
| March 1, 2024 | The Board of Directors adopted a resolution ratifying the creation of the Series A Preferred Stock. |
| March 8, 2024 | The merger of BioRegenx, Inc. into Findit, Inc. became effective, the company name changed to BioRegenx, Inc., and new officers and directors were appointed. |
| March 14, 2024 | The company filed a Certificate of Designation and a Certificate of Correction to cure the 2013 creation of the Series A preferred shares and a press release was issued. |
Keywords
BioRegenx, Merger, GlycoCheck, Endocalyx Pro, DocSun Biomedical, Microvascular Health, AI Engine, OTC QB, Regenerative Biotherapeutics, Medical Devices
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.